Significance of lymph vessel invasion identified by the endothelial lymphatic marker D2-40 in node negative breast cancer

Modern Pathology

Volumn 20, Issue 2, 2007, Pages 183-191

  Arnaout Alkarain, Angel ^a   Kahn, Harriette J ^a   Narod, Steven A ^b   Sun, Ping A ^b   Marks, Alexander N ^a,c  

^a WOMEN S COLLEGE HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

Author keywords

D2 40; Lymph vessel invasion; Node negative breast cancer

Indexed keywords

BIOLOGICAL MARKER; CD31 ANTIGEN; ESTROGEN RECEPTOR; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY D2 40; PROGESTERONE RECEPTOR; UNCLASSIFIED DRUG;

ADULT; ARTICLE; ARTIFACT; BREAST CARCINOMA; CANCER INVASION; CANCER LOCALIZATION; CANCER RECURRENCE; CANCER SIZE; CANCER SURVIVAL; CLINICAL FEATURE; CONTROLLED STUDY; CORRELATION ANALYSIS; DATA BASE; FOLLOW UP; HISTOLOGY; HUMAN; HUMAN TISSUE; INVASIVE CARCINOMA; LYMPH NODE METASTASIS; MULTIVARIATE ANALYSIS; OVERALL SURVIVAL; PATHOLOGY; PRIORITY JOURNAL; SURVIVAL TIME; VASCULAR ENDOTHELIUM;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; BREAST NEOPLASMS; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; LYMPH NODES; LYMPHATIC METASTASIS; LYMPHATIC VESSELS; MIDDLE AGED; NEOPLASM CIRCULATING CELLS; NEOPLASM INVASIVENESS; PROGNOSIS; RECEPTORS, ESTROGEN; TUMOR MARKERS, BIOLOGICAL;

EID: 33947280524     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.3800728     Document Type: Article

References (45)

1. Fisher B, Bauer M, Wickerham DC, et al. Relation of number of positive nodes to prognosis of patients with primary breast cancer. An NSABP update. Cancer 1983;52:1551-1557.
2. Rosen PP, Saigo PE, Braun Jr DW, et al. Predictors of recurrence in stage 1 (T1, N0 M0) breast carcinoma. Ann Surg 1981;193:15-25.
3. Roses DF, Bell DA, Flotte TJ, et al. Pathologic predictors of recurrence in Stage 1 (T1, N0 M0) breast cancer. Am J Clin Pathol 1982;78:817-820.
4. Bettelheim R, Penman HG, Thornton-Jones H, et al. Prognostic significance of peritumoral vascular invasion in breast cancer. Br J Cancer 1984;50:771-777.
5. Bettelheim R, Munro-Neville A. Lymphatic and vascular channel involvement within infiltrative breast carcinoma as a guide to prognosis at the time of primary surgical treatment. Letter. Lancet 1981;2:631.
6. Clemente CG, Boracchi P, Andreola S, et al. Peritumural lymphatic invasion in patients with node-negative mammary duct carcinoma. Cancer 1992;69:1396-1403.
7. Lauria R, Perrone F, Carlomagno C, et al. The prognostic value of lymphatic and blood vessel invasion of operable breast cancer. Cancer 1995;76:1772-1778.
8. Rosen PR, Groshen S. Factors influencing survival and prognosis in early breast cancer. (T1NOMO-T1N1MO). Surg Clin N Am 1990;70:937-962.
9. Lee AKC, DeLellis RA, Silverman ML, et al. Lymphatic and blood vessel invasion in breast carcinoma: A useful prognostic indicator? Human Pathol 1986;17:984-987.
10. Yiangou C, Shousha S, Sinnett HD. Primary tumour characteristics and axillary lymph node status in breast cancer. Br J Cancer 1999;80:1974-1978.
11. De Laurentiis M, Gallo C, De Placido S, et al. A predictive index of axillary nodal involvement in operable breast cancer. Br J Cancer 1996;73:1241-1247.
12. Chua B, Ung O, Taylor R, et al. Frequency and predictors of axillary lymph node metastases in invasive breast cancer. ANZ J Surg 2001;71:723-728.
13. Shoup M, Malinzak L, Weisenberger J, et al. Predictors of axillary lymph node metastasis in T1 breast carcinoma. Am Surg 1999;65:748-752.
14. Goldhirsch A, Glick JH, Gelber RD, et al. Meeting highlights: international expert consensus on the primary therapy of early breast cancer 2005. Ann Oncol 2005;16:1569-1583.
15. De Mascarel I, Bonichon F, Durand M, et al. Obvious peritumoral emboli: An elusive prognostic factor reappraised. Multivariate analysis of 1320 node-negative breast cancers. Eur J Cancer 1998;34:58-65.
16. Gilchrist KW, Gould VE, Hirschl S, et al. Interobserver variation in the identification of breast carcinoma in intramammary lymphatics. Hum Pathol 1982;13:170-172.
17. Rosen PR. Tumor emboli in intramammary lymphatics in breast carcinoma: pathologic criteria for diagnosis and clinical significance. Pathol Annu 1983;18:215-232.
18. Saigo PE, Rosen PP. The application of immunohistochemical stains to identify endothelial-lined channels in mammary carcinoma. Cancer 1987;59:51-54.
19. Bettelheim R, Mitchell D, Gusterston BA. Immunohistochemistry in the identification of vascular invasion in breast cancer. J Clin Pathol 1984;37:364-366.
20. Hanau CA, Machera H, Miettinen M. Immunohistochemical evaluation of vascular invasion in carcinomas with five different markers. App Immunohistochem 1993;1:46-50.
21. Partanen TA, Alitalo K, Miettinen M. Lack of lymphatic vascular specificity of vascular endothelial growth factor receptor3 in 185 vascular tumors. Cancer 1999;86:2406-2412.
22. Valtola R, Salven P, Heikkila P, et al. VEGFR-3 and its ligand VEGF-C are associated with angiogenesis in breast cancer. Am J Pathol 1999;154:1381-1390.
23. Jackson DG. The lymphatics revisited. New perspectives from the Hyaluronan receptor LYVE-1. Trends Cardiovasc Med 2003;13:1-7.
24. Prevo R, Banerji S, Ferguson D, et al. Mouse LYVE-1 is an endocytic receptor for hyaluronan in lymphatic endothelium. J Biol Chem 2001;276:19420-19430.
25. Mouta CC, Nasser SM, di Tomaso E, et al. LYVE-1 is not restricted to lymph vessels: expression in normal liver blood sinusoids and in human liver cancer and cirrhosis. Cancer Res 2001;61:8079-8084.
26. Wilting J, Tomarev SI, Christ B, et al. Lymphangioblasts in embryonic lymphangiogenesis. Lymphat Res Biol 2003;1:33-40.
27. Breiteneder-Geleff S, Matsui K, Soleiman A, et al. Podoplanin, a novel 43-Kd membrane protein of glomerular epithelial cells, is down-regulated in puromycin nephrosis. Am J Pathol 1997;151:1141-1152.
28. Schoppmann SF, Birner P, Studer P, et al. Lymphatic microvessel density and lymphovascular invasion assessed by anti-podoplanin immunostaining in human breast cancer. Anticancer Res 2001;21:2351-2355.
29. Birner P, Obermair A, Schindl M, et al. Selective immunohistochemical staining of blood and lymph vessels reveals independent prognostic influence of blood and lymphatic invasion in early-stage cervical cancer. Clin Cancer Res 2001;7:93-97.
30. Marks A, Sutherland DR, Bailey D, et al. Characterisation and distribution of an oncofetal antigen (M2A antigen) expressed on testicular germ tumors. Br J Cancer 1999;80:569-578.
31. Kahn HJ, Bailey D, Marks A. Monoclonal antibody D2-40, a new marker of lymphatic endothelium, reacts with Kaposi's sarcoma and a subset of angiosarcomas. Mod Pathol 2002;15:434-440.
32. Schacht V, Dadras SS, Johnson LA, et al. Up-regulation of the lymphatic marker podoplanin, a mucin-type transmembrane glycoprotein, in human squamous cell carcinomas and germ cell tumors. Am J Pathol 2005;66:913-921.
33. Evangelou E, Kyzas PA, Trikalinos T. Comparison of the diagnostic accuracy of lymphatic endothelial markers; Bayesian approach. Mod Pathol 2005;18:1490-1497.
34. Kahn HJ, Marks A. A new monoclonal antibody, D2-40, for detection of lymphatic invasion in primary tumors. Lab Invest 2002;82:1255-1257.
35. Niakosari F, Kahn HJ, Marks A, et al. Detection of lymphatic invasion in primary melanoma with monoclonal antibody D2-40. A new selective immunohistochemical marker of lymphatic endothelium. Arch Dermatol 2005;141:440-444.
36. Van den Eynden GG, Van der Auwera I, Van Laere SJ, et al. Distinguishing blood and lymph vessel invasion in breast cancer: a prospective immunphistochemical study. Br J Cancer 2006;94:1643-1649.
37. Van der Auwera I, Van den Eynden GG, Colpaert C, et al. Tumor lymphangiogenesis in inflammatory breast cancer: a histomorphometric study. Clin Cancer Res 2005;166:913-921.
38. Jackson DG, Prevo R, Clasper S, et al. LYVE-1, the lymphatic system and tumor lymphangiogenesis. Trends Immunol 2001;6:317-321.
39. Schoppmann SF, Bayer G, Aumayr K, , et al, and the Austrian Breast and Colorectal Cancer Study group. Prognostic value of lymphangiogenesis and lymphovascular invasion in invasive breast cancer. Ann Surg 2004;240:306-312.
40. Cunnick GH, Jiang WG, Gomez KF, et al. Lymphangiogenesis and breast cancer metastasis. Histol Histopathol 2002;17:863-870.
41. Williams CSM, Leek RD, Robson AM, et al. Absence of lymphangiogenesis and intratumoral lymph vessels in human metastatic breast cancer. J Pathol 2003;2:195-206.
42. Vleugel MM, Bos R, van der Groep P, et al. Lack of lymphangiogenesis during breast carcinogenesis. J Clin Pathol 2004;57:746-751.
43. Choi WWL, Lewis MM, Lawson D, et al. Angiogenic and lymphangiogenic microvessel density in breast carcinoma: correlation with clinicopathologic parameters and VEGF-family gene expression. Mod Pathol 2005;18:143-152.
44. Agarwal B, Saxena R, Morimiya A, et al. Lymphangiogenesis does not occur in breast cancer. Am J Surh Pathol. 2005;29:1449-1455.
45. Beasley NJP, Prevo R, Banerji S, et al. Intratumoral lymphangiogenesis and lymph node metastases in head and neck cancer. Cancer Res 2002;62:1315-1320.